Clinical Trial Update: Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase 2 study evaluating a triple-drug regimen of glofitamab, polatuzumab vedotin, and zuberitamab in newly diagnosed diffuse large B-cell lymphoma. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Columvi (glofitamab)
• Polivy (polatuzumab vedotin)
• Zuberitamab (Zuberitamab)

Snippet

Sponsor: Li Zhiming | Conditions: DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy | Phase 2 | Status: NOT_YET_RECRUITING